From Cell Culture to Patient Benefit: Understanding Drug Development Through Regulatory Science

The development of a new oncology drug is often described as a sequence of laboratory experiments, animal studies, clinical trials, regulatory approval, and reimbursement. However, this view does not explain why each stage is necessary or why promising therapies often fail. This paper argues that each stage addresses a distinct scientific question that previous evidence cannot fully answer. As development progresses from cell culture experiments to clinical trials, regulatory review, post-marketing surveillance, and reimbursement, the definition of a "successful" drug evolves from biological activity to meaningful patient benefit. Using regulatory practices in the United States, Japan, and China, this paper examines how different systems manage scientific uncertainty while protecting patient safety. Regulatory policies are understood not as isolated administrative procedures, but as responses to evidence gaps throughout drug development. Finally, the paper discusses how this perspective may improve oncology drug development in China through stronger evidence generation, earlier regulatory communication, and improved patient access without compromising scientific rigor.